---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-127766"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2023-12-20T23:59:59+00:00"
generated_at: "2026-06-07T09:42:54.887437+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Federal Circuit cancels key Tyvaso patent; Liquidia may launch Yutrepia sooner

## Summary
- Court affirmed IPR decision canceling claims of U.S. Patent No. 10,716,793 covering Tyvaso and Tyvaso DPI.
- Liquidia can seek final FDA approval for Yutrepia unless the decision is reversed on further appeal.
- United Therapeutics can request rehearing or petition the Supreme Court; patent claims remain valid until appeals exhausted.
- Separate lawsuit filed Sep 2023 alleges Yutrepia amendments infringe new patent (11,826,327) expiring Jan 2042.
- FDA tentatively approved Yutrepia for PAH in Nov 2021; final approval also requires lifting of District Court order.

## SEC filing metadata
- accession: 0001104659-23-127766
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2023-12-20T23:59:59+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000110465923127766/0001104659-23-127766-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000110465923127766/tm2333408d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-127766
- JSON: https://secwatch.observer/filing/0001104659-23-127766.json
- Plain text: https://secwatch.observer/filing/0001104659-23-127766.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.